at Caladrius Biosciences, Losordo is optimistic about a Phase 3 trial (this is the final step before FDA approval) injecting CD34+ cells into patients with critical limb ischemia, a chronic condition in which blood supply to the lower extremities is so severely restricted that the tissue starts to break down. If he’s successful, this could be the key to improving circulation in a wide variety of other conditions, strengthening that life force of healthy oxygenated blood.
